期刊文献+

基因治疗在下尿路功能障碍治疗中的应用现状

Application of gene therapy in lower urinary tract dysfunction
原文传递
导出
摘要 下尿路功能障碍可由中枢和外周神经系统以及尿路上皮和逼尿肌的病变导致。随着人们对下尿路研究的不断深入,临床上出现多种治疗下尿路功能障碍的新方法和新药物,但是对症状严重的患者效果仍不尽如人意。基因治疗为下尿路功能障碍的治疗提供了一种全新的途径。本文对目前国内外基因治疗在下尿路功能障碍的应用及基因导入载体的种类和优缺点进行综述。 Lower urinary tract dysfunction is caused by pathophysiological alterations of central and peripheral nervous systems, as well as urothelium and detrusor. Recent researches have increased treatment options thus many new medical care and drugs have emerged for lower urinary tract symptoms. Nevertheless, doctors still ex- perience refractory cases. Gene therapy offer a new therapeutic approach. In this article, we review the current status of gene therapy for lower urinary tract dysfunction and the advantages and disadvantages of gene delivery systems.
出处 《临床泌尿外科杂志》 2013年第8期636-639,共4页 Journal of Clinical Urology
基金 国家十二五科技支撑计划项目(编号2012BA134B02) 国家自然科学基金资助项目(81270847 81070607)
关键词 下尿路功能障碍 基因治疗 间质性膀胱炎 膀胱过度活动症 lower urinary tract dysfunction gene therapy~ interstitial cystitis~ overactive bladder
  • 相关文献

参考文献26

  • 1Miyazato M, Sasatomi K, Hiragata S, et al. GABA receptor activation in the lumbosacral spinal cord de- creases detrusor overactivity in spinal cord injured rats [J]. J Urol, 2008, 179(3),1178-83.
  • 2Miyazato M, Sugaya K, Goins W F, et al. Herpes simplex virus vector-mediated gene delivery of glutamic acid decarboxylase reduces detrusor overactivity in spinal cord-injured rats[J]. Gene Ther, 2009, 16(5):660-668.
  • 3Miyazato M, Sugaya K, Saito S, et al. Suppression of detrusor-sphincter dyssynergia by herpes simplex virus vector mediated gene delivery of glutamic acid decar- boxylase in spinal cord injured rats[J]. J Urol, 2010, 184(3): 1204-1210.
  • 4Yokoyama H, Sasaki K, Franks M E, et al. Gene therapy for bladder overactivity and nociception with herpes simplex virus vectors expressing preproenkephalin[J]. Hum Gene Ther, 2009, 20(1):63-71.
  • 5Chuang Y C, Chou A K, Wu P C, et al. Gene therapy for bladder pain with gene gun particle encoding pro- opiomelanocortin cDNA[J]. J Urol, 2003, 170 (5) : 2044-2048.
  • 6Sasaki K, Chancellor M B, Goins W F, et al. Gene therapy using replication-defective herpes simplex virus vectors expressing nerve growth factor in a rat model of diabetic cystopathy[J]. Diabetes, 2004, 53 (10) : 2723 -2730.
  • 7Liu H T, Kuo H C. Urinary nerve growth factor levels are increased in patients with bladder outlet obstruction with overactive bladder symptoms and reduced after successfulmedical treatment[J]. Urology, 2008, 72 (1): 104- 108.
  • 8Kim J C, Kim D B, Seo S I, et al. Nerve growth factor and vanilloid receptor expression, and detrusor instability, after relieving bladder outlet obstruction in rats [J]. BJU Int, 2004, 94(6):915-918.
  • 9ChuangYC, Fraser M O, Yu Y, et al. The role of bladder afferent pathways in bladder hyperactivity in- duced by the intravesical administration of nerve growth factor[J]. J Urol, 2001, 165(3) :975-979.
  • 10Tyagi P, Banerjee R, Basu S, et al. Intravesical antisense therapy for cystitis using TAT-peptide nucleic acid conjugates[J]. Mol Pharm, 2006, 3(4):398-406.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部